翻訳と辞書 |
Remogliflozin etabonate : ウィキペディア英語版 | Remogliflozin etabonate
Remogliflozin etabonate (INN/USAN)〔(Statement on a nonproprietory name adopted by the USAN council )〕 is a proposed drug of the gliflozin class for the treatment of type 2 diabetes, investigated by GlaxoSmithKline. Remogliflozin is now being developed by BHV Pharma with Islet Sciences. == Clinical trials == Remogliflozin etabonate (RE) was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels. Remogliflozin etabonate has been studied at doses up to 1000 mg. A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Remogliflozin etabonate」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|